Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
28
12
2019
accepted:
12
06
2020
revised:
20
05
2020
pubmed:
22
6
2020
medline:
22
6
2021
entrez:
22
6
2020
Statut:
ppublish
Résumé
HLA haploidentical hematopoietic stem cell transplantation (HSCT), i.e., HSCT from a 1-HLA-haplotype-mismatched family donor, has been successfully performed even as a second transplantation for posttransplant relapse. Is the haploidentical the limit of HLA mismatches in HSCT? In order to explore the possibility of HLA-mismatched HSCT from family donors beyond haploidentical relatives, we conducted a prospective phase I/II study of 2-HLA-haplotype-mismatched HSCT (2-haplo-mismatch HSCT). We enrolled 30 patients with posttransplant relapse (acute myeloid leukemia: 18, acute lymphoblastic leukemia: 11, non-Hodgkin lymphoma: 1). 2-haplo-mismatch HSCT was performed as the second to sixth transplantations. The donors were siblings (n = 12), cousins (n = 16), and second cousins (n = 2). The conditioning regimen consisted of fludarabine, cytarabine, melphalan, low-dose anti-thymocyte globulin, and 3 Gy of total body irradiation. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus, methylprednisolone, and mycophenolate mofetil. All patients achieved neutrophil engraftment, except for a case of early death. The cumulative incidences of grades II-IV and III-IV acute GVHD were 36.7% and 16.7%, respectively. The overall survival at 1 year, relapse, and non-relapse mortality rates was 30.1%, 38.9%, and 44.3%, respectively. Considering the poor prognosis of posttransplant relapse, 2-haplo-mismatch HSCT can be an alternative option in a second or third transplantation.
Identifiants
pubmed: 32564055
doi: 10.1038/s41409-020-0980-8
pii: 10.1038/s41409-020-0980-8
doi:
Types de publication
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-83Références
Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004;34:721–7.
pubmed: 15322568
doi: 10.1038/sj.bmt.1704645
Lim ABM, Curley C, Fong CY, Bilmon I, Beligaswatte A, Purtill D, et al. Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Intern Med J. 2018;48:276–85.
pubmed: 28628276
doi: 10.1111/imj.13522
Choi EJ, Lee JH, Lee JH, Park HS, Ko SH, Seol M, et al. Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Blood Res. 2018;53:288–93.
pubmed: 30588465
pmcid: 6300680
doi: 10.5045/br.2018.53.4.288
Ruutu T, de Wreede LC, van Biezen A, Brand R, Mohty M, Dreger P, et al. Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015;50:1542–50.
pubmed: 26367221
doi: 10.1038/bmt.2015.186
Spitzer B, Perales MA, Kernan NA, Prockop SE, Zabor EC, Webb N, et al. Second allogeneic stem cell transplantation for acute leukemia using a chemotherapy-only cytoreduction with clofarabine, melphalan, and thiotepa. Biol Blood Marrow Transplant. 2016;22:1449–54.
pubmed: 27184623
pmcid: 4989237
doi: 10.1016/j.bbmt.2016.05.001
Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, et al. Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes. Bone Marrow Transplant. 2016;51:186–93.
pubmed: 26437057
doi: 10.1038/bmt.2015.221
Weisdorf D. The role of second transplants for leukemia. Best Pract Res Clin Haematol. 2016;29:359–64.
pubmed: 27890260
pmcid: 5127597
doi: 10.1016/j.beha.2016.10.011
Orti G, Sanz J, Bermudez A, Caballero D, Martinez C, Sierra J, et al. Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico. Biol Blood Marrow Transplant. 2016;22:584–8.
pubmed: 26631751
doi: 10.1016/j.bbmt.2015.11.012
Taga T, Murakami Y, Tabuchi K, Adachi S, Tomizawa D, Kojima Y, et al. Role of second transplantation for children with acute myeloid leukemia following posttransplantation relapse. Pediatr Blood Cancer. 2016;63:701–5.
pubmed: 26670954
doi: 10.1002/pbc.25866
Aljasem HA, Messner HA, Lipton JH, Kim DDH, Viswabandya A, Thyagu S, et al. Outcome following second allogeneic hematopoietic cell transplantation: a single-center experience. Eur J Haematol. 2018;100:308–14.
pubmed: 29240253
doi: 10.1111/ejh.13015
Schneidawind C, Hagmaier V, Faul C, Kanz L, Bethge W, Schneidawind D. Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia. Ann Hematol. 2018;97:2491–500.
pubmed: 30066039
doi: 10.1007/s00277-018-3454-y
Yaniv I, Krauss AC, Beohou E, Dalissier A, Corbacioglu S, Zecca M, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant. 2018;24:1629–42.
pubmed: 29548831
doi: 10.1016/j.bbmt.2018.03.002
Lund TC, Ahn KW, Tecca HR, Hilgers MV, Abdel-Azim H, Abraham A, et al. Outcomes after second hematopoietic cell transplantation in children and young adults with relapsed acute leukemia. Biol Blood Marrow Transplant. 2019;25:301–6.
pubmed: 30244103
doi: 10.1016/j.bbmt.2018.09.016
Gyurkocza B, Storb R, Chauncey TR, Maloney DG, Storer BE, Sandmaier BM. Second allogeneic hematopoietic cell transplantation for relapse after first allografts. Leuk lymphoma. 2019;60:1758–66.
pubmed: 30668198
pmcid: 6594865
doi: 10.1080/10428194.2018.1542149
Gorgeis J, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, et al. T cell-replete HLA haploidentical donor transplantation with post-transplant cyclophosphamide is an effective salvage for patients relapsing after an HLA-matched related or matched unrelated donor transplantation. Biol Blood Marrow Transplant. 2016;22:1861–6.
pubmed: 27375124
doi: 10.1016/j.bbmt.2016.06.026
Haen SP, Groh C, Schumm M, Backert L, Loffler MW, Federmann B, et al. Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. Ann Hematol. 2017;96:817–27.
pubmed: 28247058
doi: 10.1007/s00277-017-2941-x
Imus PH, Blackford AL, Bettinotti M, Iglehart B, Dietrich A, Tucker N, et al. Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2017;23:1887–94.
pubmed: 28754545
pmcid: 5881910
doi: 10.1016/j.bbmt.2017.07.014
Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood. 2011;117:936–41.
pubmed: 20966170
doi: 10.1182/blood-2010-06-288506
Ringden O, Labopin M, Ciceri F, Velardi A, Bacigalupo A, Arcese W, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447–55.
pubmed: 26293645
doi: 10.1038/leu.2015.232
Ikegame K, Tanji Y, Kitai N, Tamaki H, Kawakami M, Fujioka T, et al. Successful treatment of refractory T-cell acute lymphoblastic leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling. Bone Marrow Transplant. 2003;31:507–10.
pubmed: 12665848
doi: 10.1038/sj.bmt.1703858
pmcid: 12665848
Ikegame K, Mukouchi C, Kunitomi A, Konaka Y, Kawakami M, Nishida S, et al. Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. Bone Marrow Transplant. 2003;31:1165–8.
pubmed: 12796797
doi: 10.1038/sj.bmt.1704064
pmcid: 12796797
Ogawa H, Ikegame K, Kawakami M, Tsuboi A, Kim EH, Hosen N, et al. Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. Transplantation. 2004;78:488–9.
pubmed: 15316386
doi: 10.1097/01.TP.0000128627.28212.D7
pmcid: 15316386
Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2006;12:1073–84.
pubmed: 17084371
doi: 10.1016/j.bbmt.2006.06.007
pmcid: 17084371
Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Exp Hematol. 2008;36:1–8.
pubmed: 17920757
doi: 10.1016/j.exphem.2007.08.013
Ikegame K, Yoshida T, Yoshihara S, Daimon T, Shimizu H, Maeda Y, et al. Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: a prospective multicenter phase I/II study in Japan. Biol Blood Marrow Transplant. 2015;21:1495–505.
pubmed: 25921715
doi: 10.1016/j.bbmt.2015.04.012
pmcid: 25921715
Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplant. 2015;50 Suppl 2:S37–9.
pubmed: 26039205
doi: 10.1038/bmt.2015.93
Zhang YY, Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, et al. FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients. Bone Marrow Transplant. 2019;54:1462–70.
pubmed: 30710101
doi: 10.1038/s41409-019-0456-x
pmcid: 30710101
Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, et al. Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:325–32.
pubmed: 27888014
doi: 10.1016/j.bbmt.2016.11.016
pmcid: 27888014
Rimando J, Slade M, DiPersio JF, Westervelt P, Gao F, Liu C, et al. HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Adv. 2018;2:3590–601.
pubmed: 30563883
pmcid: 6306877
doi: 10.1182/bloodadvances.2018025437
Ikegame K, Kaida K, Yoshihara S, Yoshihara K, Ishii S, Inoue T, et al. Spousal hematopoietic stem cell transplantation. Int J Hematol. 2017;105:646–57.
pubmed: 28013483
doi: 10.1007/s12185-016-2168-y
Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8:575–81.
pubmed: 12042807
doi: 10.1038/nm0602-575
Keil F, Prinz E, Moser K, Mannhalter C, Kalhs P, Worel N, et al. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival. Transplantation. 2003;76:230–6.
pubmed: 12865815
doi: 10.1097/01.TP.0000071862.42835.76
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304.
pubmed: 4153799
doi: 10.1097/00007890-197410000-00001
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21:389–401.e1.
pubmed: 25529383
doi: 10.1016/j.bbmt.2014.12.001
pmcid: 25529383
Eizuru Y, Minematsu T, Minamishima Y, Ebihara K, Takahashi K, Tamura K, et al. Rapid diagnosis of cytomegalovirus infections by direct immunoperoxidase staining with human monoclonal antibody against an immediate-early antigen. Microbiol Immunol. 1991;35:1015–22.
pubmed: 1663573
doi: 10.1111/j.1348-0421.1991.tb01623.x
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
pubmed: 23208313
pmcid: 23208313
doi: 10.1038/bmt.2012.244
Tamaki H, Ikegame K, Kawakami M, Fujioka T, Tsuboi A, Oji Y, et al. Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. Leukemia. 2003;17:2052–4.
pubmed: 14513058
doi: 10.1038/sj.leu.2403092
Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transplant. 2018;24:1099–102.
pubmed: 29452245
pmcid: 6439277
doi: 10.1016/j.bbmt.2018.02.005
Inamoto Y, Ito M, Suzuki R, Nishida T, Iida H, Kohno A, et al. Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy. Bone Marrow Transplant. 2009;44:43–9.
pubmed: 19139727
doi: 10.1038/bmt.2008.419
Sorensen BS, Szer J, Shaw B, Korhonen M, Mengling T, Fechter M, et al. Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. Bone Marrow Transplant. 2016;51:1016–8.
pubmed: 26974269
doi: 10.1038/bmt.2016.59
Sorensen CD, Moller BK, Olesen G, Hokland P, Hokland M. Complete donor chimerism following 0/10 HLA-mismatched unrelated donor allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018;53:1578–82.
pubmed: 29884849
doi: 10.1038/s41409-018-0229-y
Maeda Y, Ugai T, Kondo E, Ikegame K, Murata M, Uchida N, et al. HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. Haematologica. 2019;104:1055–61.
pubmed: 30523056
pmcid: 6518881
doi: 10.3324/haematol.2018.204438
Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 1989;320:197–204.
pubmed: 2643045
doi: 10.1056/NEJM198901263200401
Ikegame K, Kaida K, Yoshihara S, Fujiwara M, Taniguchi K, Kato R, et al. Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients. Int J Hematol. 2012;96:101–8.
pubmed: 22628189
doi: 10.1007/s12185-012-1097-7
Kanda J, Ikegame K, Fuji S, Kurokawa M, Kanamori H, Fukuda T, et al. Haploidentical and matched sibling donor hematopoietic cell transplantation for patients with HLA-homozygous haplotypes. Biol Blood Marrow Transplant. 2016;22:2031–7.
pubmed: 27492794
doi: 10.1016/j.bbmt.2016.07.020
Petrus MJ, Williams JF, Eckhaus MA, Gress RE, Fowler DH. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant. 2000;6:182–9.
pubmed: 10816026
doi: 10.1016/S1083-8791(00)70041-3
Dankers MK, Witvliet MD, Roelen DL, de Lange P, Korfage N, Persijn GG, et al. The number of amino acid triplet differences between patient and donor is predictive for the antibody reactivity against mismatched human leukocyte antigens. Transplantation. 2004;77:1236–9.
pubmed: 15114091
doi: 10.1097/01.TP.0000120385.03278.28
Heemskerk MB, Roelen DL, Dankers MK, van Rood JJ, Claas FH, Doxiadis II, et al. Allogeneic MHC class I molecules with numerous sequence differences do not elicit a CTL response. Hum Immunol. 2005;66:969–76.
pubmed: 16360836
doi: 10.1016/j.humimm.2005.06.007
Heemskerk MB, Cornelissen JJ, Roelen DL, van Rood JJ, Claas FH, Doxiadis II, et al. Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:193–200.
pubmed: 17529995
doi: 10.1038/sj.bmt.1705721
Huo MR, Pei XY, Li D, Chang YJ, Xu LP, Zhang XH, et al. Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1 on outcomes in haploidentical stem cell transplantation. Bone Marrow Transplant. 2018;53:600–8.
pubmed: 29335631
doi: 10.1038/s41409-017-0072-6
pmcid: 29335631
Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transplant. 2018;24:627–32.
pubmed: 29197681
doi: 10.1016/j.bbmt.2017.11.030
pmcid: 29197681
Sano H, Mochizuki K, Akaihata M, Kobayashi S, Ohto H, Kikuta A. T-cell-rich HLA-haploidentical hematopoietic stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia without posttransplant tyrosine kinase inhibitor therapy. Pediatr Blood Cancer. 2017;64. https://doi.org/10.1002/pbc.26242 .
Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:736–44.
pubmed: 29498106
doi: 10.1002/ajh.25082
pmcid: 29498106
Vago L, Perna SK, Zanussi M, Mazzi B, Barlassina C, Stanghellini MT, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88.
pubmed: 19641204
doi: 10.1056/NEJMoa0811036
pmcid: 19641204
Villalobos IB, Takahashi Y, Akatsuka Y, Muramatsu H, Nishio N, Hama A, et al. Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. Blood. 2010;115:3158–61.
pubmed: 20124217
doi: 10.1182/blood-2009-11-254284
Sano H, Mochizuki K, Kobayashi S, Ono S, Ikeda K, Ohto H, et al. Two occurrences of leukemia relapse due to mismatched hla loss after haploidentical stem cell transplantation from different family donors with kir ligand mismatch. J Pediatr Hematol/Oncol. 2020;42:e104–e106.
doi: 10.1097/MPH.0000000000001443
Onoe K, Gotohda T, Nishihori H, Aranami T, Iwabuchi C, Iclozan C, et al. Positive and negative selection of T cell repertoires during differentiation in allogeneic bone marrow chimeras. Transpl Immunol. 2003;12:79–88.
pubmed: 14551035
doi: 10.1016/S0966-3274(03)00012-1